Table 1.
The characteristics of all patients.
| Characteristics | Overall (n = 1715) | IHD (n = 1363) | Non-IHD (n = 352) |
|---|---|---|---|
| Number (%) or Mean ± SD [Median; interquartile range] | |||
| Gender; Male | 1397 (81.5) | 1161 (85.2) | 236 (67.0) |
| Age (years old) | 64.6 ± 11.5 | 65.1 ± 10.9 | 62.7 ± 13.4 |
| BMI (kg/m2) | 24.3 ± 4.1 | 24.6 ± 4.0 | 23.3 ± 4.4 |
| Current smoker | 386 (22.5) | 313 (23.0) | 73 (20.7) |
| Family history of IHD | 445 (26.1) | 372 (27.3) | 73 (20.7) |
| Hb (g/dL) | 13.3 ± 2.0 | 13.3 ± 1.9 | 13.5 ± 2.3 |
| Creatinine (mg/dL) | 1.66 ± 2.54 | 1.72 ± 2.65 | 1.42 ± 2.03 |
| eGFR (mL/min/1.73 m2) | 64.8 ± 26.3 | 64.9 ± 26.6 | 64.6 ± 25.1 |
| UA (mg/dL) | 6.0 ± 1.5 | 5.9 ± 1.4 | 6.3 ± 1.9 |
| FBS (mg/dL) | 120.4 ± 39.6 | 123.1 ± 41.4 | 110.0 ± 29.0 |
| HbA1c (%) | 6.2 ± 1.1 | 6.3 ± 1.1 | 5.9 ± 0.9 |
| TG (mg/dL) | 124.5 ± 103.7 | 127.9 ± 110.9 | 111.3 ± 67.9 |
| HDL-C (mg/dL) | 51.9 ± 15.7 | 51.1 ± 15.2 | 55.2 ± 16.9 |
| LDL-C (mg/dL) | 102.9 ± 31.4 | 101.4 ± 30.8 | 108.4 ± 33.1 |
| LDL-C/HDL-C | 2.14 ± 0.92 | 2.14 ± 0.87 | 2.15 ± 1.08 |
| CRP (mg/dL) | 0.58 ± 1.61 | 0.57 ± 1.66 | 0.61 ± 1.41 |
| BNP (pg/mL) | [48.0; 17.4–153.8] | [38.7; 15.4–123.3] | [103.7; 34.6–243.0] |
| Left ventricular hemodynamic parameters | |||
| LVEDVI (mL/m2) | 68.4 ± 23.9 | 64.8 ± 19.3 | 82.0 ± 33.2 |
| LVESVI (mL/m2) | 31.6 ± 19.4 | 28.9 ± 15.7 | 42.0 ± 27.4 |
| LVEF (%) | 56.1 ± 12.1 | 57.2 ± 10.8 | 51.8 ± 15.3 |
| LVEDP (mmHg) | 17.1 ± 8.5 | 16.9 ± 8.7 | 17.9 ± 7.8 |
| SVI (ml/m²) | 39.2 ± 12.2 | 39.2 ± 12.0 | 39.2 ± 12.3 |
| Underlying cardiovascular disease | |||
| Ischemic heart disease | 1363 (79.5) | 1363 | — |
| Acute coronary syndrome | 113 (6.6) | 113 (8.3) | — |
| Angina pectoris | 1216 (70.9) | 1216 (89.2) | — |
| Cardiomyopathy | 168 (9.8) | 33 (2.4) | 135 (38.4) |
| Valvular disease | 191 (11.1) | 71 (5.2) | 120 (34.1) |
| Arrhythmia | 133 (7.8) | 58 (4.3) | 75 (21.3) |
| Atrial fibrillation | 112 (6.5) | 44 (3.2) | 68 (19.3) |
| Other than AF | 21 (1.2) | 14 (1.0) | 7 (2.0) |
| Hypertension | 1269 (74.0) | 1049 (77.0) | 220 (62.5) |
| Type-2 diabetes mellitus | 647 (37.7) | 566 (41.5) | 81 (23.0) |
| Dyslipidemia | 1239 (72.2) | 1077 (79.0) | 162 (46.0) |
| Renal dysfunction* | 554 (32.3) | 428 (31.4) | 126 (35.8) |
| Hemodialysis | 179 (10.4) | 150 (11.0) | 29 (8.2) |
| Medication | |||
| Antiplatelet agent | 1158 (67.5) | 1057 (77.5) | 101 (28.7) |
| Anticoagulant agent | 170 (9.9) | 101 (7.4) | 69 (19.6) |
| ACE inhibitors | 301 (17.6) | 256 (18.8) | 45 (12.8) |
| ARBs | 647 (37.7) | 545 (40.0) | 102 (29.0) |
| Beta blockers | 633 (36.9) | 537 (40.0) | 96 (27.3) |
| Calcium channel blockers | 923 (53.8) | 804 (59.0) | 119 (33.8) |
| Diuretics | 320 (18.7) | 216 (15.8) | 104 (29.5) |
| Statins | 904 (52.7) | 824 (60.5) | 80 (22.7) |
| Non- Statin for dyslipidemia | 223 (13.0) | 199 (14.6) | 24 (6.8) |
| Oral antidiabetic agents | 402 (23.4) | 355 (26.0) | 47 (13.4) |
| Insulin | 177 (10.3) | 157 (11.5) | 20 (5.7) |
| Anti-hyperuricemia | 280 (16.3) | 220 (16.1) | 60 (17.0) |
Hb, hemoglobin; UA, uric acid; FBS, fasting blood sugar; HbA1c, hemoglobin A1c; TG, triglycerides; HDL-C, high-density lipoprotein; LDL-C, low-density lipoprotein; ACE, angiotensin-converting enzyme; ARBs, angiotensin II type I-receptor blockers; BMI, body mass index; BNP, B-type natriuretic peptide; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; IHD, ischemic heart disease; LVEDP, left ventricular end-diastolic pressure; LVEDVI, left ventricular end-diastolic volume index; LVEF, left ventricular ejection fraction; LVESVI, left ventricular end-systolic volume index; and SVI, stroke volume index.
*Renal dysfunction = eGFR < 60 mL/min/1.73 m2.